Fewer than a tenth of patients who could benefit from obesity jabs including Wegovy can access them, states the World Health Organization as it issues its first guidance on the medications.
Given in excess of 1,000,000,000 people worldwide now living with obesity, it is advocating for increased and just availability to GLP-1 medication.
Per estimates, over two billion will be obese by 2030 if no action is taken.
"The latest guidance acknowledges that obesity is a chronic disease that can be treated with holistic and ongoing care," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are major barriers to broad access to the injections that can help people shift substantial weight, explains the organization.
Weight-Loss Drug Scarcity
Despite the current best projected outlook, the supply of these medications might only reach approximately 100 million people – under 10% of eligible patients, as stated by the health organization.
The recommendation encourages nations and manufacturers to expand access, through measures including voluntary licensing.
A patent on a key compound – the main ingredient of the drug Wegovy – is scheduled to end in a number of nations in 2026.
The Way Obesity Injections Operate
GLP-1 drugs imitate a natural hormone to reduce digestion speed, curb appetite and increase feelings of fullness so users consume fewer calories.
Individuals typically begin shedding pounds in the initial weeks of beginning the regular doses.
Research points to users may put most of the weight back on after a year of discontinuing the treatment, as their normal hunger return.
To be overweight or obese elevates your chance for developing health problems, like diabetes, heart disease, brain attack, and some cancers.
Excess weight concerns people in all nations and was associated with 3.7 million fatalities worldwide in 2024, per the WHO.
